Humira® | FAMHP

Active substance	Adalimumab
Holder	AbbVie SA/NV
Status	Closed
Indication	Treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies
Public documents	Approbation
	Information for the patient
	Infromed consent for children under 12 years old Informed consent for patients older than 12 years
Last update	17/07/2017